Memory T cell rapid recall is driven by memory-specific AP-1 recruitment determined by epigenome and co-factor interactions

preprint OA: closed
Full text JSON View at publisher
AI-generated deep summary by claude@2026-07, 2026-07-03 · read from full text

The paper investigates how CD4 T cell memory cells execute rapid recall gene expression upon antigen re-exposure, focusing on the roles of activation-inducible transcription factors AP-1 and NF-κB and how epigenetic regulation enables faster responses. Using experimental analyses of memory versus naïve T cells, the authors find that AP-1 is required for induction of rapid recall genes and that memory cells show enhanced, memory-specific AP-1 binding, which is supported by increased chromatin accessibility and reduced DNA methylation at regulatory elements. They report that DNA methylation likely modulates AP-1 co-factor binding (e.g., ETS proteins) or overall accessibility rather than directly altering the AP-1 motif, and they observe overlap between AP-1/NF-κB binding sites and autoimmune/inflammatory disease risk variants. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

ABSTRACT CD4 T cell memory is essential for long-lasting protective immunity to repeat infections. Unlike naïve T cells, memory cells possess rapid recall ability to quickly produce effector molecules in response to antigen re-exposure. This ability was shown to be associated with epigenetic gene poising. Here, we examine how the activation-inducible transcription factors, AP□1 and NF□κB, regulate rapid recall gene expression. We found that AP-1 is required for their induction and that the enhanced induction of rapid recall genes in memory cells is associated with memory-specific binding of AP□1. Memory-specific AP□1 binding, in turn, is enabled by enhanced chromatin accessibility and reduced DNA methylation at regulatory elements. As the AP-1 DNA-binding motif itself does not contain methylatable CpGs, methylation likely affects the binding of AP-1 co-factors, such as ETS proteins, or accessibility of the region in general. Finally, both common and memory-specific AP□1/NF□κB binding sites show strong overlap with autoimmune and inflammatory disease risk variants, highlighting the clinical relevance of memory T cell epigenetic regulation.
Full text 1,541 characters · extracted from oa-doi-fallback · click to expand
ABSTRACT CD4 T cell memory is essential for long-lasting protective immunity to repeat infections. Unlike naïve T cells, memory cells possess rapid recall ability to quickly produce effector molecules in response to antigen re-exposure. This ability was shown to be associated with epigenetic gene poising. Here, we examine how the activation-inducible transcription factors, AP□1 and NF□κB, regulate rapid recall gene expression. We found that AP-1 is required for their induction and that the enhanced induction of rapid recall genes in memory cells is associated with memory-specific binding of AP□1. Memory-specific AP□1 binding, in turn, is enabled by enhanced chromatin accessibility and reduced DNA methylation at regulatory elements. As the AP-1 DNA-binding motif itself does not contain methylatable CpGs, methylation likely affects the binding of AP-1 co-factors, such as ETS proteins, or accessibility of the region in general. Finally, both common and memory-specific AP□1/NF□κB binding sites show strong overlap with autoimmune and inflammatory disease risk variants, highlighting the clinical relevance of memory T cell epigenetic regulation. Competing Interest Statement A.B. is a co-founder of and M.K. and A.B. are employed part-time by Datirium, LLC. Datirium created the Scientific Data Analysis platform, https://scidap.com, used to analyze the next-generation sequencing data in this study. A.B. is an unpaid member of the Scientific Advisory Board of Lysosomal & Rare Disorders Research & Treatment Center (LDRTC), LLC.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00